The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Frequent BRCA1/2 and BARD1 germline mutations in triple-negative breast cancer patients.
Jacques De Greve
No relevant relationships to disclose
Sylvia De Brakeleer
No relevant relationships to disclose
Christine Desmedt
No relevant relationships to disclose
Sofie Joris
No relevant relationships to disclose
Christos Sotiriou
No relevant relationships to disclose
Martine J. Piccart-Gebhart
No relevant relationships to disclose
Ingrid Pauwels
No relevant relationships to disclose
Erik Teugels
No relevant relationships to disclose